PL3388426T3 - Związki do ochrony komórek - Google Patents

Związki do ochrony komórek

Info

Publication number
PL3388426T3
PL3388426T3 PL18174182.8T PL18174182T PL3388426T3 PL 3388426 T3 PL3388426 T3 PL 3388426T3 PL 18174182 T PL18174182 T PL 18174182T PL 3388426 T3 PL3388426 T3 PL 3388426T3
Authority
PL
Poland
Prior art keywords
cell protection
protection compounds
compounds
cell
protection
Prior art date
Application number
PL18174182.8T
Other languages
English (en)
Inventor
Adrianus Cornelis Van Der Graaf
Andre Heeres
Johannes Paulus Gerardus Seerden
Original Assignee
Sulfateq B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sulfateq B.V. filed Critical Sulfateq B.V.
Publication of PL3388426T3 publication Critical patent/PL3388426T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/66—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Dentistry (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
PL18174182.8T 2012-12-19 2013-12-18 Związki do ochrony komórek PL3388426T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2010010A NL2010010C2 (en) 2012-12-19 2012-12-19 Compounds for protection of cells.

Publications (1)

Publication Number Publication Date
PL3388426T3 true PL3388426T3 (pl) 2023-12-27

Family

ID=47790452

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13818495T PL2935232T3 (pl) 2012-12-19 2013-12-18 Związki do ochrony komórek
PL18174182.8T PL3388426T3 (pl) 2012-12-19 2013-12-18 Związki do ochrony komórek

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL13818495T PL2935232T3 (pl) 2012-12-19 2013-12-18 Związki do ochrony komórek

Country Status (20)

Country Link
US (3) US10123529B2 (pl)
EP (2) EP3388426B1 (pl)
JP (2) JP6359558B2 (pl)
AU (1) AU2013364538B9 (pl)
CA (1) CA2895701C (pl)
CY (1) CY1120682T1 (pl)
DK (1) DK2935232T3 (pl)
ES (2) ES2686599T3 (pl)
HR (1) HRP20181434T1 (pl)
HU (1) HUE039373T2 (pl)
LT (1) LT2935232T (pl)
MX (1) MX371337B (pl)
NL (1) NL2010010C2 (pl)
PL (2) PL2935232T3 (pl)
PT (1) PT2935232T (pl)
RS (1) RS57762B1 (pl)
SI (1) SI2935232T1 (pl)
SM (1) SMT201800463T1 (pl)
WO (1) WO2014098586A1 (pl)
ZA (1) ZA201504602B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102137450B1 (ko) 2012-07-12 2020-07-27 콘드리온 아이피 비.브이. 미토콘드리아 질환을 치료하기 위한 크로마닐 유도체
NL2010010C2 (en) * 2012-12-19 2014-06-23 Sulfateq B V Compounds for protection of cells.
NL2013012B1 (en) 2014-06-17 2016-07-05 Sulfateq Bv Compounds for the treatment of chronic obstructive airway diseases.
CA2986300C (en) * 2015-05-22 2024-02-20 Sulfateq B.V. Compound for the prophylaxis or treatment of organ damage
US11285130B2 (en) 2017-04-05 2022-03-29 Khondrion Ip B.V. Treatment of mitochondrial diseases
EP3672593B1 (en) 2017-08-25 2024-12-18 Sulfateq B.V. Medicaments for the treatment of vasoconstriction related diseases or disorders
WO2019038360A1 (en) * 2017-08-25 2019-02-28 Sulfateq B.V. 6-CHROMANOL DERIVATIVES FOR USE AS A MEDICINAL PRODUCT
CA3079483A1 (en) 2017-11-22 2019-05-31 Khondrion Ip B.V. Compounds as mpges-1 inhibitors
AU2019359473B2 (en) * 2018-10-11 2025-11-20 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for cell culture
JP7838964B2 (ja) * 2019-04-24 2026-04-01 ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ ヒト多能性幹細胞からの侵害受容器の分化
NL2024431B1 (en) * 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimer’s disease
NL2025730B1 (en) 2020-06-02 2022-01-20 Sulfateq Bv Compounds for treatment of sepsis
NL2026511B1 (en) * 2020-09-21 2022-05-24 Sulfateq Bv Compounds for treatment of heart failure
US20240051931A1 (en) * 2020-12-03 2024-02-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Hdac inhibitors
NL2031091B1 (en) 2022-02-28 2023-09-07 Sulfateq Bv Chromanol compounds for treatment or prophylaxis of ageing and ageing-associated disorders
EP4729606A1 (en) 2024-10-17 2026-04-22 Sulfateq B.V. Methods for the cryopreservation of cells

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA739471B (en) 1972-12-22 1974-08-28 Hoffmann La Roche Chromane derivatives
DE3484473D1 (de) 1984-12-06 1991-05-23 Kuraray Co Chroman-verbindungen und deren herstellung.
JPH0816108B2 (ja) 1986-02-21 1996-02-21 株式会社クラレ ３，４−ジヒドロ−２ｈ−ベンゾピラン誘導体及びその医薬用途
CA1338012C (en) 1987-04-27 1996-01-30 John Michael Mccall Pharmaceutically active amines
JPH02215778A (ja) * 1989-02-14 1990-08-28 Kuraray Co Ltd ３，４―ジヒドロ―２ｈ―ベンゾピラン誘導体及びその医薬用途
FR2676056B1 (fr) 1991-05-03 1993-07-16 Adir Nouveaux derives du benzopyranne leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JP3074043B2 (ja) 1991-09-06 2000-08-07 エーザイ株式会社 動脈硬化治療・予防剤
CA2073479A1 (en) * 1992-07-08 1994-01-09 Tai-Wing Wu Synergistic compositions
US5643943A (en) * 1994-12-23 1997-07-01 Alcon Laboratories, Inc. Systemic administration of esters and amides of antioxidants which may be used as antioxidant prodrug therapy for oxidative and inflammatory pathogenesis
ZA973848B (en) 1996-05-06 1997-12-02 Reddy Research Foundation Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them.
JP3093170B2 (ja) 1996-09-19 2000-10-03 株式会社ジャパンエナジー ヒドロキノン誘導体及びその医薬用途
US6809088B2 (en) * 1997-03-24 2004-10-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
US6335445B1 (en) * 1997-03-24 2002-01-01 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
DE69716592T2 (de) * 1997-05-02 2003-06-26 Dr. Reddy's Laboratories Ltd., Hyderabad Neue heterozyklische verbindungen mit antidiabetischen, hypolipiddaemischen und blutdrucksenkenden eigenschaften, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die diese enthalten
CA2319131A1 (en) 1998-01-26 1999-07-29 Walter H. Moos Mitochondria protecting agents for treating mitochondria associated diseases
US6002040A (en) 1998-05-14 1999-12-14 The Standard Oil Company Reduced pressure drop in acrylonitrile absorber via direct contact spray heat exchange
WO2000000194A1 (en) 1998-06-27 2000-01-06 Photogenesis, Inc. Ophthalmic uses of ppargamma agonists and ppargamma antagonists
AR019190A1 (es) 1998-07-08 2001-12-26 Sod Conseils Rech Applic Derivados de 2-aminopiridinas, productos intermedios para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y su uso para preparar medicamentos
CN1131217C (zh) * 1998-07-31 2003-12-17 日本曹达株式会社 苯基吡咯化合物和其制备方法及抗高血脂药
EP1006108A1 (en) 1998-12-01 2000-06-07 Cerebrus Pharmaceuticals Limited 3-Hydroxy-2(1H)-pyridinone or 3-hydroxy-4(1H)-pyridinone derivatives useful as reactive oxygen species (ROS) scavengers
WO2001030141A1 (en) 1999-10-22 2001-05-03 Quadrant Healthcare (Uk) Limited Platelet stabilisation
US6768008B2 (en) * 2000-04-24 2004-07-27 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
EP1276730A2 (en) * 2000-04-24 2003-01-22 ARYx Therapeutics Thiazolidinedione analogues and their use for the treatment of diabetes
KR100389127B1 (ko) * 2000-10-09 2003-06-25 동부한농화학 주식회사 벤조피라닐 헤테로고리 유도체, 그의 제조방법 및 그를포함하는 약학적 조성물
DE10262084B4 (de) * 2002-05-17 2009-12-24 Dr. Franz Köhler Chemie GmbH Protektive Lösung zur Verhinderung von Ischämieschäden
US7964339B2 (en) 2007-02-09 2011-06-21 Canadian Blood Services Cold storage of modified platelets
PL2220030T3 (pl) * 2007-11-06 2016-07-29 Bioelectron Tech Corp Pochodne 4-(p-chinonylo)-2-hydroksybutanamidu do leczenia chorób mitochondrialnych
FR2945938B1 (fr) * 2009-06-02 2011-06-10 Oreal Utilisation de derives d'acide chroman-2-carboxylique en coloration des fibres keratiniques humaines, composition les comprenant, procede de coloration et dispositif
NL2004569C2 (en) * 2010-04-16 2011-10-18 Angteq B V Compounds for prevention of cell injury.
NL2010010C2 (en) * 2012-12-19 2014-06-23 Sulfateq B V Compounds for protection of cells.
NL2013012B1 (en) * 2014-06-17 2016-07-05 Sulfateq Bv Compounds for the treatment of chronic obstructive airway diseases.
CA2986300C (en) * 2015-05-22 2024-02-20 Sulfateq B.V. Compound for the prophylaxis or treatment of organ damage
NL2024431B1 (en) * 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimer’s disease
NL2025730B1 (en) * 2020-06-02 2022-01-20 Sulfateq Bv Compounds for treatment of sepsis
NL2026511B1 (en) * 2020-09-21 2022-05-24 Sulfateq Bv Compounds for treatment of heart failure

Also Published As

Publication number Publication date
JP2016511743A (ja) 2016-04-21
PL2935232T3 (pl) 2018-12-31
RS57762B1 (sr) 2018-12-31
US20210227822A1 (en) 2021-07-29
ZA201504602B (en) 2017-07-26
PT2935232T (pt) 2018-10-11
CA2895701C (en) 2022-05-31
EP3388426A3 (en) 2018-11-28
HUE039373T2 (hu) 2018-12-28
US20190098890A1 (en) 2019-04-04
EP2935232B1 (en) 2018-06-13
JP6359558B2 (ja) 2018-07-18
CY1120682T1 (el) 2019-12-11
AU2013364538A1 (en) 2015-07-09
EP3388426A2 (en) 2018-10-17
AU2013364538B2 (en) 2017-05-25
SMT201800463T1 (it) 2018-11-09
US11006626B2 (en) 2021-05-18
WO2014098586A1 (en) 2014-06-26
ES2686599T3 (es) 2018-10-18
US10123529B2 (en) 2018-11-13
MX2015007883A (es) 2016-03-04
AU2013364538B9 (en) 2017-06-22
NL2010010C2 (en) 2014-06-23
JP6684861B2 (ja) 2020-04-22
EP2935232A1 (en) 2015-10-28
JP2018162280A (ja) 2018-10-18
EP3388426C0 (en) 2023-07-05
LT2935232T (lt) 2018-09-25
MX371337B (es) 2020-01-27
ES2954292T3 (es) 2023-11-21
HRP20181434T1 (hr) 2018-10-19
SI2935232T1 (sl) 2018-10-30
DK2935232T3 (en) 2018-09-17
EP3388426B1 (en) 2023-07-05
CA2895701A1 (en) 2014-06-26
US20150342174A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
HRP20171005T1 (hr) Spojevi imidazopirolidinona
DK2859055T3 (da) Polymercoatings
DK2825087T3 (da) Otoscanner
DK2839013T3 (da) Ikke-disruptiv-gen-targetering
EP2892086A4 (en) RECTANGULAR SECONDARY BATTERY
DK2864053T3 (da) Separator
HRP20170226T1 (hr) Spoj pirazinkarboksamida
DK2873977T3 (da) Dobbeltdækker-rørdispenser
EP2835843A4 (en) SEPARATOR
DE112012006109A5 (de) Okklusionsschienenanordnung
DK2854722T3 (da) Stomipose
DE102013108016A8 (de) Sicherheitshülle
UA24760S (uk) Шрифт
FR2995111B1 (fr) Protection contre canaux auxiliaires
EP2911230A4 (en) CELL
PT2825212T (pt) Resumo
IL239447A0 (en) Novel compounds
HRP20181434T1 (hr) Spojevi za zaštitu stanica
EP2903015A4 (en) BREAKERS
DK2825157T3 (da) Aminosyrelipider
EP2813537A4 (en) SEPARATOR
DK2804611T3 (da) Chitosanafledte forbindelser
DE112012006214T8 (de) Wulstringwickler
EP2920370A4 (en) POST
DK2831122T3 (da) Anthocyanidin-kompleks